Tanzania Medical Device Classification: Classes A, B, C and D under GN 315

1. Key takeaways

Tanzania classifies medical devices into four classes: A (low risk), B (low-to-moderate risk), C (moderate-to-high risk) and D (high risk). The statutory basis is Section 5(1) of GN 315, and the specific rules are set out in the First Schedule, whose rule set is aligned with the Global Harmonization Task Force (GHTF). This alignment means manufacturers familiar with GHTF-derived systems in other jurisdictions will recognize the logic, but must still verify each rule against the Tanzanian text rather than importing conclusions from elsewhere.

Section 5(2) provides the single tie-breaking rule: where a device falls into more than one class, the class representing the higher risk applies.

The allocation of responsibility for classification is: the manufacturer determines the class according to the intended purpose (the June 2024 Compendium, Part I §3.1, states expressly “The manufacturer is responsible for classifying the device”), while TMDA reserves the right to make the decision on the class of a device. This dual structure — manufacturer proposes, authority can override — is workable only when the classification rationale is documented and defensible, because an undocumented classification is impossible to defend once TMDA questions it during screening or assessment.

2. Legal basis

3. Expert insights

Insight 1: The official classification examples are themselves the cheapest calibration reference available.

Part I §3.1 of the June 2024 Compendium and the TMDA website procedure page give the same set of examples: Class A covers surgical retractors and tongue depressors; Class B covers hypodermic needles and suction equipment; Class C covers lung ventilators and bone fixation plates; Class D covers heart valves and implantable defibrillators. These four groups span the full spectrum from passive low-value consumables to active implants and serve as the first calibration step in any self-assessment. Match your device against the nearest official example before applying abstract rules; a large gap from every example is itself a signal to review the analysis.

Insight 2: The highest-rule-wins principle cuts both ways and is a frequent source of disputes.

Section 5(2) and the closing wording of Part I §3.1 are consistent: in the incidence that more than one classification rule is applicable to the device, the rules resulting in the highest risk classification shall be applicable to the device. In practice, an active device incorporating software may trigger both an active-device rule and a software rule; a device incorporating a medicinal substance may trigger both the device rule and the stricter medicinal-substance rule. As long as any single rule points to the higher class, the application must be prepared for that higher class — attempting to submit under the lower class invites rejection at the §3.4.2 screening step on the ground that the wrong product class was applied, and the file is returned.

Insight 3: Classification links to route, fees, review time and audit in one chain.

Once the class is fixed in Tanzania, four consequences lock in simultaneously: first, whether the device follows registration or notification (only Class A devices that are non-active, non-measuring and non-sterile may use notification); second, the registration fee tier (Class A at USD 500; Classes B, C and D at USD 2500); third, the assessment timeline (approximately 43 working days for Classes A and B, approximately 93 working days for Classes C and D); fourth, whether a manufacturing-site quality audit is triggered (Classes C and D, and invasive or sterile Classes A and B). Classification is not a technical detail; it is the master switch for project budget and schedule.

Insight 4: The manufacturer decides and TMDA can revise — this allocation requires the classification basis to be written down.

Part I §3.1 makes classification the manufacturer’s responsibility while TMDA reserves the final decision. The submission must therefore include a classification rationale document explaining rule by rule which rules were applied and why other rules do not apply. The TMDA website procedure page makes this the first step: “Classify your medical device… then Confirm the procedure for authorization i.e., registration or notification”. A rationale that merely names the class without walking through the applicable rules gives TMDA grounds to reclassify and restart the review clock.

4. Practical recommendations

1. Complete the classification determination before quoting price or schedule. Any timeline or fee quoted while the class is unsettled is unreliable and creates commercial risk.
2. List every rule that could possibly apply and take the highest class. Do not document only the rule that seems the closest fit.
3. Prepare the classification rationale as a standalone document, submit it with the application, and re-review it at every change — a change in risk classification is expressly listed in item 4(a) of TMDA/DMD/MDA/G/003 as a situation that cannot be handled as a variation and requires a fresh application.
4. Double-check every Class A conclusion. Class A is the only class that may use notification, and notification approval is valid for only 3 years (registration certificates run 5 years); a wrong call here cascades into the entire downstream compliance rhythm.

5. Verification checklist

• □ The classification has been determined rule by rule against the current rules in the First Schedule of GN 315.
• □ All potentially applicable rules have been listed and the highest class taken.
• □ A classification rationale document has been prepared, stating the applicable rules and the reasons for excluding the others.
• □ The four-way linkage between class, route, fee tier, review timeline and quality audit has been confirmed.
• □ The intended purpose statement has been confirmed consistent with the classification outcome (a change of purpose can change the class).

Regulatory information verified as of 29 October 2026. All provisions cited in this article were checked against the texts officially published by TMDA (Section 5 and the First Schedule of GN. No. 315, and Part I §3.1 and Part V of the June 2024 Compendium of Guidelines); the content is re-reviewed whenever the regulations are updated.

• Local resources in Tanzania: GRZAN can coordinate licensed local responsible persons (LRP) and distributor resources covering online submission, sample delivery, quality audit support and port clearance.
• Service capabilities: classification determination, route selection between registration and notification, technical documentation (CSDT/STED) preparation and localization, GMDN coding and grouping strategy, clinical evidence organization, software and AI device submissions, change management, vigilance and PMS reporting, annual retention fees and renewal management.
• Contact: hito.lin@grzan.cn; website www.grzan.cn.